Cytokinetics (CYTK) Change in Accured Expenses (2010 - 2026)

Cytokinetics (CYTK) has reported Change in Accured Expenses for 17 consecutive years, with -$6.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 56.76% year-over-year to -$6.2 million; the TTM figure through Mar 2026 stood at $41.8 million (up 674.14% YoY), while the FY2025 annual figure was $33.6 million, up 136.94% from the prior year.
• Change in Accured Expenses declined to -$6.2 million in Q1 2026 per CYTK's latest filing, from $26.4 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $32.1 million in Q4 2023 and bottomed at -$14.4 million in Q1 2025.
• Historically, Change in Accured Expenses has averaged $4.1 million across 5 years, with a median of $4.2 million in 2024.
• On a YoY basis, Change in Accured Expenses climbed as much as 9253.56% in 2023 and fell as far as 287.96% in 2023.
• Cytokinetics' Change in Accured Expenses stood at -$351000.0 in 2022, then surged by 9253.56% to $32.1 million in 2023, then sank by 68.64% to $10.1 million in 2024, then soared by 161.67% to $26.4 million in 2025, then slumped by 123.56% to -$6.2 million in 2026.
• Business Quant data shows CYTK's Change in Accured Expenses at -$6.2 million in Q1 2026, $26.4 million in Q4 2025, and $7.6 million in Q3 2025.